Absci (ABSI) Revenue & Revenue Breakdown
Absci Revenue Highlights
Latest Revenue (Y)
$5.72M
Latest Revenue (Q)
$898.00K
Absci Revenue by Period
Absci Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $5.72M | -0.50% |
| 2022-12-31 | $5.75M | 20.18% |
| 2021-12-31 | $4.78M | 0.04% |
| 2020-12-31 | $4.78M | 132.04% |
| 2019-12-31 | $2.06M | - |
Absci generated $5.72M in revenue during NA 2023, up -0.50% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Absci Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $898.00K | 165.68% |
| 2023-12-31 | $338.00K | -54.57% |
| 2023-09-30 | $744.00K | -77.90% |
| 2023-06-30 | $3.37M | 165.33% |
| 2023-03-31 | $1.27M | -18.50% |
| 2022-12-31 | $1.56M | -34.28% |
| 2022-09-30 | $2.37M | 136.43% |
| 2022-06-30 | $1.00M | 22.34% |
| 2022-03-31 | $819.00K | -43.60% |
| 2021-12-31 | $1.45M | -5.65% |
| 2021-09-30 | $1.54M | 111.40% |
| 2021-06-30 | $728.00K | -31.51% |
| 2021-03-31 | $1.06M | -61.03% |
| 2020-12-31 | $2.73M | 197.82% |
| 2020-09-30 | $916.00K | 62.41% |
| 2020-06-30 | $564.00K | -1.40% |
| 2020-03-31 | $572.00K | - |
Absci generated $898.00K in revenue during Q1 2024, up 165.68% compared to the previous quarter, and up 57.68% compared to the same period a year ago.
Absci Revenue Breakdown
Absci Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Jun 21 |
|---|---|
| Collaborative Revenue | $136.00K |
| Technology Development Revenue | $592.00K |
Latest
Absci's latest quarterly revenue breakdown by segment (product or service), as of Jun 21: Technology Development Revenue (81.32%), and Collaborative Revenue (18.68%).
Absci Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Jun 21 |
|---|---|
| Collaborative Revenue | $136.00K |
| Technology Development Revenue | $592.00K |
Latest
Absci's latest quarterly revenue breakdown by geography, as of Jun 21: Technology Development Revenue (81.32%), and Collaborative Revenue (18.68%).
Absci Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| DTIL | Precision BioSciences | $48.73M | $576.00K |
| RXRX | Recursion Pharmaceuticals | $44.58M | $14.42M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| VECT | VectivBio | $27.34M | $676.00K |
| RLAY | Relay Therapeutics | $25.55M | - |
| EXAI | Exscientia | $24.96M | $5.29M |
| AFMD | Affimed | $8.28M | $155.00K |
| ABSI | Absci | $5.72M | $898.00K |
| XFOR | X4 Pharmaceuticals | - | $560.00K |
| AVRO | AVROBIO | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ZURA | Zura Bio | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| GRPH | LENZ Therapeutics | - | - |
| ELEV | Elevation Oncology | - | - |
| CFRX | ContraFect | - | - |
| SANA | Sana Bio | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |